Showing results (541-550 of 577) with videos related to

Sort By:
Pageof 58
Lancet (London, England)|April 13, 2011
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trialPaul D Griffiths, Anna Stanton, Erin McCarrell, et al.
Brain : a Journal of Neurology|August 14, 2018
Epilepsyecosystem.org: crowd-sourcing reproducible seizure prediction with long-term human intracranial EEGLevin Kuhlmann, Philippa Karoly, Dean R Freestone, et al.
Pilot and Feasibility Studies|February 17, 2024
Supporting physical activity through co-production in people with severe mental ill health (SPACES): protocol for a randomised controlled feasibility trialGareth Jones, Laura Bailey, Rebecca J Beeken, et al.
Journal of Gastroenterology and Hepatology|December 31, 2020
Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohortNikolas Plevris, James Fulforth, Spyros Siakavellas, et al.
Annals of Neurology|January 23, 2014
Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageingChristopher C Rowe, Pierrick Bourgeat, Kathryn A Ellis, et al.
Investigative Ophthalmology & Visual Science|December 2, 2024
Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular RetinopathiesMelissa A Calton, Roxanne H Croze, Christian Burns, et al.
European Urology Oncology|May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE TrialKim N Chi, Elena Castro, Gert Attard, et al.
The Lancet. Oncology|February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trialMatthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 6, 2011
Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisenseSterghios A Moschos, Manfred Frick, Bruce Taylor, et al.
Transplantation Research|May 7, 2013
Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocolRichard Haynes, Colin Baigent, Paul Harden, et al.
Pageof 58